Pharmaceuticals, Biotechnology and Life Sciences
New clinical data from phase I trial UV1-103, combining UV1 with pembrolizumab in advanced melanoma will be presented Oslo, September…
OXFORD, United Kingdom, Sept. 20, 2022 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the…
EMERYVILLE, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the…
Assigned PDUFA target action date of March 22, 2023SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ:…
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company…
— 5-fold higher neutralizing antibodies against dominant Omicron BA.5 in participants who received SCB-2019 (CpG 1018/Alum) as a heterologous third…
VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader…
SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies,…
LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market…
Congress Moves to Expand Funding for National Network of Specialized Treatment Centers and Community Organizations for Sickle Cell Disease PatientsSOUTH…